All In Biotech

Drug Trial Radar · NCT05391893

Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation

Emergency Department Atrial Fibrillation Oral Diltiazem Observation Protocol

Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

444

Actual

Start

Jun 19, 2020

Primary completion

Apr 1, 2023

Study completion Apr 1, 2023

Sponsor

Lead sponsor
Corewell Health SouthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to reduce hospital admission and decrease time to disposition through establishing an effective treatment protocol for AF and Atrial Flutter in the Emergency Department of Spectrum Health Lakeland. Secondary outcome is to measure if oral diltiazem is an effective HR controlling agent in AF RVR and Flutter.

Conditions

  • Atrial Fibrillation
  • Atrial Flutter

Interventions

  • OralDrug

    Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg

  • Intravenous drugDrug

    these patients will receive traditional treatments at provider discretion. They must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response. This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Admission RateTime frame: 1 days
  2. Treatment Success at 3 HoursTime frame: 3 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Matthew Hysell

    Saint Joseph, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.